CBIH (Cannabis Bioscience International Holdings) ROC (Joel Greenblatt) %: 0.00% (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cannabis Bioscience International Holdings ROC (Joel Greenblatt) %?

Cannabis Bioscience International Holdings CBIH +33.33% ROC (Joel Greenblatt) % is 0.00% as of Feb. 2026. The stock has 4 warning signs investors should review. Among 983 Drug Manufacturers companies, Cannabis Bioscience International Holdings ranks worse than 96.85% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cannabis Bioscience International Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was 0.00%.

The historical rank and industry rank for Cannabis Bioscience International Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:

CBIH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2936.36   Med: -25.02   Max: 54.73
Current: -2936.36

During the past 8 years, Cannabis Bioscience International Holdings's highest ROC (Joel Greenblatt) % was 54.73%. The lowest was -2936.36%. And the median was -25.02%.

CBIH's ROC (Joel Greenblatt) % is ranked worse than
96.85% of 983 companies
in the Drug Manufacturers industry
Industry Median: 11.44 vs CBIH: -2936.36

Cannabis Bioscience International Holdings's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Cannabis Bioscience International Holdings  (OTCPK:CBIH) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Cannabis Bioscience International Holdings ROC (Joel Greenblatt) % Related Terms


Cannabis Bioscience International Holdings ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Cannabis Bioscience International Holdings's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannabis Bioscience International Holdings ROC (Joel Greenblatt) % Chart

Cannabis Bioscience International Holdings Annual Data
Trend Dec06 Dec07 May09 May10 May11 May23 May24 May25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -37.52 47.75 -12.52 -1,620.00 -1,887.18

Cannabis Bioscience International Holdings Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,893.33 -5,085.71 -6,000.00 0.00 0.00

CBIH vs SXTC, UPC, NPHC: ROC (Joel Greenblatt) % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannabis Bioscience International Holdings ROC (Joel Greenblatt) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Bioscience International Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Cannabis Bioscience International Holdings's ROC (Joel Greenblatt) % falls into.



Cannabis Bioscience International Holdings ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Nov. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.022 + 0 + 0) - (0.979 + 0 + 0)
=-0.957

Working Capital(Q: Feb. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.001 + 0 + 0.001) - (1.063 + 0 + -0.00099999999999989)
=-1.06

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Cannabis Bioscience International Holdings for the quarter that ended in Feb. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Feb. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2025  Q: Feb. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.372/( ( (0 + max(-0.957, 0)) + (0 + max(-1.06, 0)) )/ 1 )
=-0.372/( ( 0 + 0 )/ 1 )
=-0.372/0
= %

Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 0.00% mean?
Cannabis Bioscience International Holdings (CBIH) has a ROC (Joel Greenblatt) % of 0.00% as of Feb. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cannabis Bioscience International Holdings and its competitors. According to the industry distribution chart, Cannabis Bioscience International Holdings ranks #952 out of 983 companies in the Drug Manufacturers industry, placing it in the top 96.8%.
Is Cannabis Bioscience International Holdings' ROC (Joel Greenblatt) % too high?
Cannabis Bioscience International Holdings' current ROC (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Cannabis Bioscience International Holdings ranks #952 out of 983 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Cannabis Bioscience International Holdings' ROC (Joel Greenblatt) % compare to SXTC and UPC?
According to the Drug Manufacturers industry distribution chart, Cannabis Bioscience International Holdings ranks #952 out of 983 companies for ROC (Joel Greenblatt) %. This places Cannabis Bioscience International Holdings in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.44, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cannabis Bioscience International Holdings and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabis Bioscience International Holdings's current ROC (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Bioscience International Holdings stock overvalued right now?
Cannabis Bioscience International Holdings (CBIH) has a current ROC (Joel Greenblatt) % of 0.00%. The current ROC (Joel Greenblatt) % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Cannabis Bioscience International Holdings (CBIH), the current ROC (Joel Greenblatt) % is 0.00% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cannabis Bioscience International Holdings Business Description

Address 6201 Bonhomme Road, Suite 435N, Houston, TX, USA, 77036
Cannabis Bioscience International Holdings Inc operates in three main areas. Firstly, the company engages in cannabis-related research and education under the trade name Pharmacology University. Secondly, it serves as both a Sponsor and a Contract Research Organization (CRO) in clinical trials, some of which involve cannabis and CBD products, under the trade name Alpha Research Institute. Lastly, the company plans to manufacture, market, and sell CBD products branded as "VitaCookies." The majority of the company's revenue comes from clinical trial contracts, while a smaller portion is generated from cannabis-related educational classes and seminars.